Rectal Cancer Treatment Guidelines

Introduction to Rectal Cancer Treatment

The American College of Surgeons and other guideline societies recommend risk-stratified treatment using preoperative therapy followed by total mesorectal excision (TME) surgery for stages II and III rectal cancer, with the specific regimen determined by tumor characteristics on MRI staging 1

For early favorable disease (cT1-2, some early cT3, N0), surgery alone using TME technique is appropriate without neoadjuvant therapy, according to the National Comprehensive Cancer Network 1, 2
For intermediate risk disease (most cT3 without threatened mesorectal fascia, some cT4a, N+), preoperative radiotherapy followed by TME is the standard approach, as recommended by the European Society for Medical Oncology 1, 2
For locally advanced disease (cT3 with threatened circumferential margin, cT4 with organ involvement), preoperative chemoradiotherapy (50 Gy in 1.8 Gy fractions with concurrent 5-FU-based therapy) followed by radical surgery 6-8 weeks later is recommended by the American Society of Clinical Oncology 1, 3

Accurate preoperative staging with rectal MRI (or endoscopic ultrasound for cT1-T2 tumors) is mandatory to select appropriate patients for neoadjuvant treatment, as emphasized by the National Cancer Institute 1, 4
At least 12 lymph nodes must be examined pathologically to ensure adequate staging, according to the College of American Pathologists 3, 4

Adjuvant chemotherapy similar to stage III colon cancer can be provided, though scientific support for efficacy is less robust than in colon cancer, as noted by the American Society of Clinical Oncology 2, 3
Delaying surgery 6-8 weeks after long-course chemoradiotherapy is essential for tumor downstaging, as recommended by the European Society for Medical Oncology 1, 3